Informa helps businesses and professionals in hundreds of ways.

Our international portfolio of live events, world-leading research publications, and innovative digital services provide specialists with the knowledge and connections they need to thrive.

TIDES Asia: Oligonucleotide & Peptide Therapeutics
24-26 Feb, 2027
Grand Nikko Tokyo DaibaTokyo
Book Now
Menu
Book Now

Workshop #1: The Scale-up Trilemma: Navigating Solid-Phase, Enzymatic and Hybrid Synthesis in Oligo CMC

Compare emerging oligonucleotide manufacturing approaches and understand the CMC, scalability, sustainability, and regulatory trade-offs shaping next-generation production.

As oligonucleotide pipelines grow in complexity, manufacturing strategy has become a critical point of differentiation. This workshop brings together the perspectives needed to evaluate solid-phase, enzymatic, and hybrid synthesis approaches, helping attendees understand how each model may impact process development, scale-up, supply strategy, and long-term commercial readiness.

Book Now

About this workshop

The oligonucleotide manufacturing landscape is evolving rapidly, with new synthesis technologies creating fresh opportunities alongside new technical and regulatory questions. This workshop explores how developers can assess the strengths, limitations, and practical implications of different production approaches, with a focus on how manufacturing choices influence CMC strategy, scalability, efficiency, and sustainability.

Solid-phase synthesis in today’s manufacturing landscape

Understand where established solid-phase approaches continue to deliver value and where developers may encounter limitations as programs scale.

Enzymatic synthesis opportunities

Explore how enzymatic methods are being considered to improve manufacturing efficiency, flexibility, and environmental performance.

Hybrid synthesis strategies

Examine how hybrid approaches may offer a middle ground between innovation and operational practicality for next-generation oligonucleotide production.

Scalability, efficiency, and sustainability trade-offs

Assess the competing priorities shaping process decisions as companies look to optimize throughput, cost, and environmental impact.

CMC complexity in emerging manufacturing models

Learn how new synthesis platforms can introduce fresh challenges in process understanding, control strategy, and comparability.

Regulatory readiness for novel synthesis technologies

Discuss how evolving production methods may affect regulatory expectations and long-term development planning.

Industry challenges we’ll address

Choosing the right synthesis approach for current and future pipeline needs

Scaling manufacturing efficiently without compromising robustness or quality

Balancing innovation with operational feasibility and supply continuity

Building CMC strategies around emerging production technologies

Improving sustainability while maintaining process performance

Preparing for regulatory expectations around newer synthesis approaches

  • VP / Head / Director of Oligonucleotide CMC
  • VP / Director of Process Development
  • Head of Manufacturing / Technical Operations
  • Director of MSAT
  • Director of Analytical Development
  • Regulatory CMC Lead
  • Oligonucleotide Platform Lead
  • CDMO Program Lead
  • Process Chemist / Senior Scientist, Oligonucleotide Development
  • Technical Project Lead, RNA Therapeutics